Tularik Limited

Amgen Inc.

Genentech, Inc.

U3 Pharma Gmbh

Immunoqure Ag

Genetech, Inc.

Daiichi Sankyo Europe Gmbh

Other

Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

U3 Pharma Ag

Mike Rothe

David V Goeddel

Eric Borges

Martin Treder

Annalisa Macagno

Zhaodan Cao

Adrian Hayday

Kai Krohn

Kai Kisand

Paert Peterson

Martin Woodward

Syeda F Y Haque

Susanne Hartmann

Larry L Green

Catherine R&eacute;gnier

Thore Hettmann

Esther Zwick-Wallasch

Yeong Song

Lin Wu

Steffen Meyer

Philip Vlaicu

Daniel Freeman

Shimobi Onuoha

Jens Niewoehner

Robert Radinsky

Part Peterson

Johannes Bange

Patricia Aus Dem Siepen

Orit Foord

Syeda F Haque

Jens Ruhe

Peter Wirtz

David Gómez-Varela

Luis A Pardo

Kerstin Dehne

Catherine Régnier

Jens Niewöhner

Kerstin Selle

Norbert Prenzel

Walter Stühmer

Hendrik Knötgen

Pärt Peterson

Dan Freeman

Bob Radinsky

Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-α antibodies as well as IFN-α binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.

Human anti-IFN-α antibodies

The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.

Antibodies directed to HER-3 and uses thereof

Provided are novel IL-32 binding molecules of human origin, particularly human anti-IL-32 antibodies as well as IL-32 binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy are described.

CDNA encoding a monoclonal anti-IL-32 antibody and methods for the production of the antibody

Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-&#x3b1; antibodies as well as IFN-&#x3b1; binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.

Human anti-IFN-&#x3b1; antibodies

The present invention provides methods for the determination of the activation level of Receptor Tyrosine kinases, e.g. phosporylated HER3, for the selection of patients for disease treatment. Methods are also provided for the evaluation of the biological and pharmacodynamic effects of an active substance and/or its efficacy in disease treatment, utilizing a tissue sample from a test subject, for example tumor material or normal tissue such as skin or hair follicle. Further, methods for the treatment of HER receptor-associated diseases are disclosed.

Activated HER3 as a marker for predicting therapeutic efficacy

Human anti-IL-32 antibodies and methods of making and using the same

Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.

Material and methods for treating or preventing HER-3 associated diseases

The present invention relates to FGFR4 antibodies including fragments or derivatives thereof and the polynucleotides encoding the antibodies. Expression vectors and host cells comprising the polynucleotides are provided. Further, the invention refers to pharmaceutical compositions comprising the FGFR4 antibodies and methods for the treatment, prevention or diagnosis of disorders associated with FGFR4 expression.

FGFR4 antibodies

The present invention refers to antibodies, particularly to monoclonal antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.

AXL antibodies

Provided herein are antigen binding proteins, e.g., human and/or monoclonal antibodies that have affinity for heparin-binding epidermal growth factor-like growth factor (HB-EGF) and neutralize the biological functions of this growth factor.

Heparin-binding epidermal growth factor-like growth factor binding proteins

Growing community of inventors

Krailling, Germany

Mike Rothe